EUVIMEDEUVIMED entdecken
Metaanalyse

Quantitative evaluation of the efficacy and safety of first-line systemic therapies for advanced hepatocellular carcinoma

Xinrui Wang, Jihan Huang, Yixiao Liu, Lijuan Wu, Ruifen Cai, Qingshan Zheng, Lujin Li

European Journal of Clinical Pharmacology · 2025

DOI: 10.1007/s00228-024-03797-0 ↗

Kurz gefasst

Metaanalyse in der Zeitschrift European Journal of Clinical Pharmacology, 2025. Verfasst von Xinrui Wang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Center for Pharmacometrics, Institute of Interdisciplinary Integrative Medicine Research, Shanghai University of Traditional Chinese Medicine, No.120…. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Antineoplastic Agents, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit nennt 39 Literaturangaben. Gefördert von: National Natural Science Funds of China, National Key Research and Development Program of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularLiver NeoplasmsAntineoplastic AgentsAntineoplastic Combined Chemotherapy ProtocolsHumansImmune Checkpoint InhibitorsSorafenibAngiogenesis InhibitorsProgression-Free SurvivalTreatment OutcomeMonte Carlo Method

Stichwörter der Autor:innen

Advanced hepatocellular carcinoma (aHCC)Model-based meta-analysis (MBMA)Overall survival (OS)Progression-free survival (PFS)Systemic therapy

Substanzen

Immune Checkpoint InhibitorsSorafenibAngiogenesis InhibitorsAntineoplastic Agents

Autor:innen und Institutionen

  • Center for Pharmacometrics, Institute of Interdisciplinary Integrative Medicine Research, Shanghai University of Traditional Chinese Medicine, No.1200 Cailun Road, Shanghai, 201203, China.
  • Center for Pharmacometrics, Institute of Interdisciplinary Integrative Medicine Research, Shanghai University of Traditional Chinese Medicine, No.1200 Cailun Road, Shanghai, 201203, China. qingshan.zheng@drugchina.net.
  • Center for Pharmacometrics, Institute of Interdisciplinary Integrative Medicine Research, Shanghai University of Traditional Chinese Medicine, No.1200 Cailun Road, Shanghai, 201203, China. lujin.li@drugchina.net.

Förderung

  • National Natural Science Funds of China
  • National Key Research and Development Program of China

Zitieren

APA

Wang, X., Huang, J., Liu, Y., Wu, L., Cai, R., Zheng, Q., & Li, L. (2025). Quantitative evaluation of the efficacy and safety of first-line systemic therapies for advanced hepatocellular carcinoma. European Journal of Clinical Pharmacology. https://doi.org/10.1007/s00228-024-03797-0

Vancouver

Wang X, Huang J, Liu Y, Wu L, Cai R, Zheng Q, et al. Quantitative evaluation of the efficacy and safety of first-line systemic therapies for advanced hepatocellular carcinoma. European Journal of Clinical Pharmacology. 2025. doi:10.1007/s00228-024-03797-0

BibTeX
@article{Wang2025,
  author = {Wang, Xinrui and Huang, Jihan and Liu, Yixiao and Wu, Lijuan and Cai, Ruifen and Zheng, Qingshan and Li, Lujin},
  title = {Quantitative evaluation of the efficacy and safety of first-line systemic therapies for advanced hepatocellular carcinoma},
  journal = {European Journal of Clinical Pharmacology},
  year = {2025},
  doi = {10.1007/s00228-024-03797-0}
}
Kostenlos starten →